Nanobiotix S.A. (NANO.PA)

EUR 3.48

(1.93%)

EBITDA Summary of Nanobiotix S.A.

  • Nanobiotix S.A.'s latest annual EBITDA in 2023 was -34.01 Million EUR , up 41.08% from previous year.
  • Nanobiotix S.A.'s latest quarterly EBITDA in 2024 Q2 was -23.24 Million EUR , down 0.0% from previous quarter.
  • Nanobiotix S.A. reported an annual EBITDA of -53.78 Million EUR in 2022, down -1.56% from previous year.
  • Nanobiotix S.A. reported an annual EBITDA of -45.6 Million EUR in 2021, down -29.9% from previous year.
  • Nanobiotix S.A. reported a quarterly EBITDA of N/A for 2023 FY, up 41.08% from previous quarter.
  • Nanobiotix S.A. reported a quarterly EBITDA of 1.41 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of Nanobiotix S.A. (2023 - 2011)

Historical Annual EBITDA of Nanobiotix S.A. (2023 - 2011)

Year EBITDA EBITDA Growth
2023 -34.01 Million EUR 41.08%
2022 -53.78 Million EUR -1.56%
2021 -45.6 Million EUR -29.9%
2020 -31.49 Million EUR 21.69%
2019 -45.01 Million EUR -61.04%
2018 -29.44 Million EUR -18.68%
2017 -24.81 Million EUR -16.1%
2016 -21.37 Million EUR -28.09%
2015 -16.68 Million EUR -79.18%
2014 -9.31 Million EUR -18.08%
2013 -7.94 Million EUR -56.84%
2012 -5.02 Million EUR -0.2%
2011 -5.01 Million EUR 0.0%

Peer EBITDA Comparison of Nanobiotix S.A.

Name EBITDA EBITDA Difference
ABIONYX Pharma SA -3.29 Million EUR -934.012%
ABIVAX Société Anonyme -133.2 Million EUR 74.462%
Adocia SA -22.73 Million EUR -49.652%
Aelis Farma SA -6.34 Million EUR -435.986%
Biophytis S.A. -13.8 Million EUR -146.443%
Advicenne S.A. -6.24 Million EUR -444.827%
genOway Société anonyme 6.35 Million EUR 635.669%
IntegraGen SA -52.5 Thousand EUR -64694.393%
Medesis Pharma S.A. -3.84 Million EUR -784.786%
Neovacs S.A. -8.44 Million EUR -302.613%
NFL Biosciences SA -4.04 Million EUR -740.12%
Plant Advanced Technologies SA 72.53 Thousand EUR 47003.35%
Quantum Genomics Société Anonyme -2.87 Million EUR -1083.895%
Sensorion SA -22.31 Million EUR -52.457%
Theranexus Société Anonyme -7.38 Million EUR -360.511%
TME Pharma N.V. -5.07 Million EUR -570.722%
Valbiotis SA -6.95 Million EUR -389.13%
TheraVet SA -517.33 Thousand EUR -6475.804%
Valerio Therapeutics Société anonyme -18.91 Million EUR -79.842%
argenx SE -199.5 Million EUR 82.948%
BioSenic S.A. -6.79 Million EUR -400.574%
Celyad Oncology SA -7.76 Million EUR -338.22%
DBV Technologies S.A. -79.53 Million EUR 57.225%
Galapagos NV 51.03 Million EUR 166.656%
Genfit S.A. -28.05 Million EUR -21.276%
GeNeuro SA -14.31 Million EUR -137.601%
Hyloris Pharmaceuticals SA -14.98 Million EUR -127.096%
Innate Pharma S.A. -7.57 Million EUR -348.918%
Inventiva S.A. -101.84 Million EUR 66.598%
MaaT Pharma SA -19.74 Million EUR -72.335%
MedinCell S.A. -20.04 Million EUR -69.705%
Onward Medical N.V. -35.23 Million EUR 3.448%
Oryzon Genomics S.A. -4.43 Million EUR -667.342%
OSE Immunotherapeutics SA -23.26 Million EUR -46.218%
Oxurion NV -16.72 Million EUR -103.353%
Pharming Group N.V. 4.98 Million EUR 782.98%
Poxel S.A. -12.17 Million EUR -179.325%
GenSight Biologics S.A. -21.73 Million EUR -56.553%
Transgene SA -27.02 Million EUR -25.884%
Financière de Tubize SA 184.57 Thousand EUR 18531.39%
UCB SA 1.26 Billion EUR 102.681%
Valneva SE -64.51 Million EUR 47.271%
Vivoryon Therapeutics N.V. -28.35 Million EUR -19.984%